Jasper Registers 284M PIPE Shares for Resale — Massive Overhang on $16.7M Micro-Cap
JSPR sits 59% above its 52-week low of $0.315.
Summary
Jasper registered 284 million PIPE shares for resale — an overhang roughly 8.5x the current float — making the July 2026 financing tradable for the first time. The company receives no proceeds; all sales benefit selling stockholders.
Key Events · Financing and Capital Events · JSPR
-
284M Resale Shares Registered
S-3 registers 284,013,011 shares issuable upon conversion of 4,655,951 PIPE Preferred Stock shares at a 61:1 ratio, subject to stockholder approval not yet obtained.
-
Massive Float Overhang
284M shares vs. 33.3M currently outstanding — a potential 8.5x increase in float if fully converted and sold. Filing fee table prices shares at $0.56 (Oct 9 average), implying $159M maximum aggregate offering value.
-
Company Receives No Proceeds
All resale proceeds go to 42 selling stockholders, including Mirador Therapeutics (53.8M shares), Affinity Healthcare Fund (30.8M), and Rubric Capital (29.5M). Jasper bears registration costs.
-
Conversion Contingent on Stockholder Vote
Preferred Stock converts automatically on the third business day after stockholder approval. If approval is not obtained within 12 months of issuance, holders may demand cash equal to fair value of undelivered shares.
Analysis · JSPR · Life Sciences
Jasper Therapeutics filed an S-3 to register 284,013,011 shares of common stock for resale by PIPE investors from the July 2026 Kira merger financing. The shares are issuable upon conversion of 4,655,951 shares of non-voting convertible preferred stock at a 61:1 ratio, subject to stockholder approval that has not yet been obtained. The registration is required under the Registration Rights Agreement and does not itself raise capital for the company — all proceeds go to selling stockholders. However, the sheer scale is staggering: 284 million shares against only 33.3 million currently outstanding represents a potential 8.5x increase in the float if fully converted and sold. The filing fee table prices the shares at $0.56 (October 9 average), implying a maximum aggregate offering value of $159 million — nearly 10x the company's current market cap of $16.7 million. This comes amid a going-concern warning, a Nasdaq delisting risk with a November 30 deadline, and a pending reverse stock split (1-for-15 to 1-for-35) approved September 30 but not yet effected. The registration makes the PIPE overhang tradable for the first time, and the market must now price in the possibility of massive selling pressure from 42 institutional holders, including Mirador Therapeutics (53.8M shares), Affinity Healthcare Fund (30.8M shares), and Rubric Capital (29.5M shares).
How filings like this one have moved
In the 30 days to Nov 5, 2026, 43.4% of the 1274 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.16%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JSPR was trading at $0.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.7M. The 52-week trading range was $0.32 to $2.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.